Dinutuximab plus transplant for high-risk neuroblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 30 years old or younger at the time of diagnosis.
- The cancer must be newly diagnosed high-risk neuroblastoma or ganglioneuroblastoma (a tumor of nerve cells).
- Your child's kidneys must work well enough, as shown by a blood test or urine test.
- Your child's liver function must be normal (a blood test checks this).
- Your child's heart must pump at least 50% of the blood out with each beat (checked by an echo or nuclear scan).
- Your child must be able to handle a stem cell collection procedure (apheresis), which is like a blood donation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This Phase 2 trial tests whether adding a drug called naxitamab to standard early (frontline) treatment improves outcomes for children with high-risk neuroblastoma. It may help by helping the immune system better target the cancer during initial induction therapy.
This Phase 2 trial studies a targeted treatment approach for children and young adults with advanced neuroblastoma (a childhood cancer). It may help by using lab-tested cancer features to guide therapy after initial treatment and transplant.
This Phase 1 study tests lab-made donor immune cells (gamma delta T cells) plus chemotherapy to treat neuroblastoma or osteosarcoma that has come back or hasn’t responded to standard treatment. It’s designed to find a safe way to give this treatment and to see how well it might work.
This trial combines the immunotherapy drug dinutuximab beta with two different chemotherapy regimens to see if it works better for children with high-risk neuroblastoma that has spread. It may be an option for newly diagnosed patients who have not had cancer treatment before.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
Hear when a new Ganglioneuroblastoma, Nodular trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.